Fluticasone Furoate Ellipta Powder
Product Images NDC 66993-168

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Fluticasone Furoate Ellipta (NDC 66993-168). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Prasco Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fluticasone Furoate Chemical Structure (Fluticasone Furoate Ellipta Spl Graphic 01)

Chemical structure of fluticasone furoate, showing the molecular arrangement including fluorine atoms, hydroxyl groups, and ester functionalities characteristic of this corticosteroid compound.*

FDA Label Image

Figure 1 (Fluticasone Furoate Ellipta Spl Graphic 02)

A chart displaying fold change and 90% confidence intervals for the pharmacokinetics (AUC and Cmax) of Fluticasone Furoate Ellipta across different populations and conditions (age, ethnicity, gender, renal and hepatic impairment). The x-axis shows change relative to reference values, while the y-axis lists population categories with corresponding dose adjustment recommendations.*

FDA Label Image

Figure 2 (Fluticasone Furoate Ellipta Spl Graphic 03)

A forest plot showing fold change and 90% confidence intervals for pharmacokinetic parameters AUC and Cmax of ketoconazole as an interacting drug. The graph depicts a scale of change relative to reference from 0.75 to 2.0, with both parameters showing values slightly above 1 and a recommendation labeled as caution.*

FDA Label Image

Figure 3 (Fluticasone Furoate Ellipta Spl Graphic 04)

A chart presenting data from three clinical trials (687, 685, 684) showing the difference from placebo with 95% confidence intervals on the vertical axis, and different fluticasone furoate treatment doses in micrograms on the horizontal axis. The chart compares various once-daily (OD) and twice-daily (BD) dosing regimens, including fluticasone furoate (FF) and fluticasone propionate (FP) treatments.*

FDA Label Image

Figure 4 (Fluticasone Furoate Ellipta Spl Graphic 05)

A line graph comparing LS mean change from baseline (mL) over 24 hours between Fluticasone Furoate ELLIPTA 100 mcg once daily and placebo. The x-axis shows planned time since dose (hours), and the y-axis shows LS mean change from baseline in mL. The graph includes two lines with markers: one solid circle line for Fluticasone Furoate ELLIPTA and one solid square line for placebo.*

FDA Label Image

Figure 5 (Fluticasone Furoate Ellipta Spl Graphic 06)

Line chart showing the least squares mean change from baseline (mL) over 24 weeks of study for Fluticasone Furoate Ellipta powder inhalation at strengths 200 mcg and 100 mcg once daily. The x-axis represents the study weeks, and the y-axis represents the lung volume change in milliliters, illustrating the response at both dosage levels over time.*

FDA Label Image

Figure 6 (Fluticasone Furoate Ellipta Spl Graphic 07)

A line graph comparing the least squares mean change from baseline in mL over planned time since dose (up to 24 hours) for fluticasone furoate Ellipta 200 mcg once daily and fluticasone propionate 500 mcg twice daily. Both treatments show changes with error bars indicating variability at each time point.*

FDA Label Image

Fluticasone Furoate Ellipta Inhaler (Fluticasone Furoate Ellipta Spl Graphic 08)

An exploded view diagram illustrating components of the Fluticasone Furoate Ellipta inhalation powder packaging. The image shows a carton, tray lid, inhaler device, desiccant packet, tray, and a patient information leaflet separately arranged to depict packaging contents.*

FDA Label Image

Figure A (Fluticasone Furoate Ellipta Spl Graphic 09)

An instructional illustration depicting a hand peeling back the foil cover of a blister pack containing circular tablets or doses, indicating how to access the powdered medication for inhalation.*

FDA Label Image

Figure B (Fluticasone Furoate Ellipta Spl Graphic 10)

An instructional illustration showing a hand discarding three tablets or pills into an open trash can with the lid removed, indicating disposal of medication.*

FDA Label Image

Figure C (Fluticasone Furoate Ellipta Spl Graphic 11)

An illustration of a respiratory inhaler device showing a labeled cover and a dose counter display reading '30'. The image depicts basic external features relevant to the device's use.*

FDA Label Image

Figure D (Fluticasone Furoate Ellipta Spl Graphic 12)

An instructional diagram showing the use of a respiratory inhalation device with labeled parts including mouthpiece, air vent, counter displaying '29', and a cover being closed with a 'click' sound indicated.*

FDA Label Image

Figure E (Fluticasone Furoate Ellipta Spl Graphic 13)

An instructional illustration showing a person inhaling powder medication from a handheld respiratory inhaler device, with arrows indicating the inhalation pathway through the mouth. This diagram visually demonstrates the correct use of a respiratory inhalation powder device.*

FDA Label Image

Figure F (Fluticasone Furoate Ellipta Spl Graphic 14)

Illustration showing a person using the Fluticasone Furoate Ellipta inhaler by placing the mouthpiece in their mouth and preparing to inhale the powder medication.*

FDA Label Image

Figure G (Fluticasone Furoate Ellipta Spl Graphic 15)

An instructional line drawing showing a person holding a Fluticasone Furoate Ellipta inhaler. The illustration focuses on the proper hand positioning, demonstrating to avoid blocking the air vent with fingers during inhalation.*

FDA Label Image

Figure H (Fluticasone Furoate Ellipta Spl Graphic 16)

An instructional illustration showing a person with their head tilted slightly back, with a clock indicating to hold breath for 3-4 seconds. This image is likely demonstrating part of the inhalation technique for using a respiratory powder inhaler.*

FDA Label Image

Figure I (Fluticasone Furoate Ellipta Spl Graphic 17)

An instructional illustration showing a person holding a Fluticasone Furoate Ellipta inhaler. The person’s mouth is positioned to inhale, with arrows indicating the direction of airflow from the mouth into the respiratory tract.*

FDA Label Image

Figure J (Fluticasone Furoate Ellipta Spl Graphic 18)

Illustration showing how to open the mouthpiece cover of a Fluticasone Furoate Ellipta inhaler by lifting it upward. The inhaler is depicted with a dose counter displaying the number 29.*

FDA Label Image

Figuer K (Fluticasone Furoate Ellipta Spl Graphic 19)

An instructional illustration showing a person rinsing their mouth and spitting into a sink, with a glass of water nearby, likely demonstrating proper oral hygiene following the use of an inhaled medication.*

FDA Label Image

Figure L (Fluticasone Furoate Ellipta Spl Graphic 20)

Illustration of the Fluticasone Furoate Ellipta inhaler device showing the dose counter window displaying the number 9, with an arrow labeled "Red" pointing to it. The device is depicted with a curved ergonomic shape and a textured grip area.*

FDA Label Image

Fluticasone Furoate 50mcg 30 Dose Carton (Fluticasone Furoate Ellipta Spl Graphic 21)

Fluticasone Furoate ELLIPTA Inhalation Powder 50 mcg label by Prasco Laboratories. The label shows the product name, strength, and indicates it is for oral inhalation only. It includes one ELLIPTA inhaler containing one foil strip of 30 blisters. Packaging features the Prasco logo and dosage details, highlighting Rx only use.*

FDA Label Image

Fluticasone Furoate 100mcg 30 Dose Carton (Fluticasone Furoate Ellipta Spl Graphic 22)

Fluticasone Furoate ELLIPTA Inhalation Powder 100 mcg label from Prasco Laboratories displays an inhaler device with orange and white coloring. The label indicates the product is for oral inhalation only, containing 100 mcg of fluticasone furoate per blister, with 30 blisters in one foil strip included in the package. Markings include the NDC 66993-167-97 and Rx only.*

FDA Label Image

Fluticasone Furoate 200mcg 30 Dose Carton (Fluticasone Furoate Ellipta Spl Graphic 23)

Packaging label for Fluticasone Furoate ELLIPTA Inhalation Powder 200 mcg by Prasco Laboratories. The label shows this respiratory inhalation powder is for oral inhalation only, with one ELLIPTA inhaler containing a foil strip of 30 blisters, each delivering 200 mcg of fluticasone furoate.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.